See analyst estimates and all valuation multiples for Pharmacies
Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
$153B | 0.4x | 10.1x | |
$38.7B | 0.3x | 10.2x | |
$27.1B | 8.4x | 33.8x | |
$9.2B | 2.2x | 35.6x | |
$8.1B | 1.0x | 19.5x | |
$7.3B | 0.2x | 3.4x | |
$6.8B | 0.9x | 9.5x | |
$6.6B | 0.6x | 11.4x | |
$6.0B | 0.8x | 9.9x | |
$5.2B | 2.0x | 15.2x | |
$4.9B | 0.7x | 11.5x | |
$4.3B | 1.7x | 10.0x | |
$4.2B | 1.2x | 10.7x | |
$3.9B | 0.4x | 9.4x | |
$3.8B | 0.6x | 9.0x | |
$3.7B | 0.2x | 5.7x | |
$3.7B | 0.7x | 8.3x | |
$3.6B | 0.6x | 8.3x | |
$2.9B | 1.0x | 57.8x | |
$2.9B | 0.8x | 6.5x | |
$2.8B | 0.8x | 11.0x | |
$2.5B | 0.8x | 7.5x | |
$2.4B | 1.3x | 9.7x | |
$2.2B | 0.3x | 4.4x | |
$1.8B | 2.2x | 6.7x | |
$1.8B | 0.8x | 10.0x | |
$1.4B | 0.4x | 6.1x | |
$1.2B | 1.6x | 20.5x | |
$1.2B | 1.1x | 9.4x | |
$1.2B | 0.4x | n/a | |
$1.1B | 0.4x | 9.1x | |
$1.1B | n/a | n/a | |
$995M | n/a | n/a | |
$974M | 0.4x | 6.7x | |
$973M | n/a | n/a | |
$926M | 0.7x | n/a | |
$850M | 1.4x | 15.9x | |
$722M | n/a | n/a | |
$666M | n/a | n/a | |
$627M | n/a | n/a | |
$534M | 0.4x | -11.0x | |
$411M | 0.2x | 17.8x | |
$279M | 0.1x | n/a | |
$270M | n/a | n/a | |
$220M | n/a | n/a | |
$218M | 0.5x | 9.1x | |
$135M | 0.1x | 3.6x | |
$110M | n/a | n/a | |
$70.1M | 0.5x | 13.5x | |
$46.2M | n/a | n/a | |
$29.0M | 0.4x | 47.5x | |
$26.9M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Pharmacies